Sandbox Reserved 390: Difference between revisions

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Revision as of 15:57, 3 December 2012 view source Eyitayo Akoda (talk \| contribs) 187 edits No edit summary ← Older edit		Revision as of 15:58, 3 December 2012 view source Eyitayo Akoda (talk \| contribs) 187 edits No edit summary Newer edit →
Line 3:		Line 3:
	The purpose of this page is to explain a semisynthetic derivative of [http://en.wikipedia.org/wiki/Podophyllotoxin podophyllotoxin] [[Image:PODO.png\|thumb\|right\|50 px\|Chemical structure of podophyllotoxin]] (etoposide) that demonstrates antitumor activity by inhibiting DNA topoisomerase II, thereby inhibiting DNA re-ligation which lead to apoptosis of the cancer cell and also, to describe the mechanisms of resistance of etoposide.		The purpose of this page is to explain a semisynthetic derivative of [http://en.wikipedia.org/wiki/Podophyllotoxin podophyllotoxin] [[Image:PODO.png\|thumb\|right\|50 px\|Chemical structure of podophyllotoxin]] (etoposide) that demonstrates antitumor activity by inhibiting DNA topoisomerase II, thereby inhibiting DNA re-ligation which lead to apoptosis of the cancer cell and also, to describe the mechanisms of resistance of etoposide.


	<ref name=”Wu CC, Li TK, Farh L, Lin LY, Lin TS, Yu YJ, Yen TJ, Chiang CW, Chan NL. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science. 2011 Jul 22;333(6041):459-62.</ref>